Skip to content

Released May 7, 2024, before the open

10-Q filed May 7, 2024, 37 days after period end · 0000950170-24-053966

Q1 2024 · 10-Q
Revenue$188.61M+7.7% vs Q1 2023−5.9% vs Q4 2023
Net Income-$36.02MN/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.95N/M vs Q1 2023no prior Q4 2023 on file
Gross Profit$127,242,000+15.3%
Operating Income-$29,337,000N/M
Operating Cash Flow-$18,595,000N/M
Free Cash Flowderived-$29,138,000N/M
Margins · derived
Gross margin67.5%+4.5 pt vs Q1 2023
Operating margin-15.6%+18.5 pt vs Q1 2023
Net margin-19.1%+15.7 pt vs Q1 2023

What the release said

The release

Same quarter

MetricQ1 2024Q1 2023Q1 2022Q1 2021
Revenue$188.61M$175.20M$106.42M$105.59M
Net Income-$36.02M-$60.94M-$4.46M-$5.82M
EPS Diluted-$0.95-$1.71-$0.22-$0.30

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR